Amgen Inc.'s (NASDAQ:AMGN) Aranesp and Epogen, along with J&J's Procrit, are the popular anemia treatment drugs that are affected.
They must now include a boxed warning that reflects "the increased risk of mortality as well as life-threatening side effects," Goldman analyst Lawrence Keusch said in a research note. There are also changes to dosing and administration instructions.
Mr. Keusch expects the J&J will be able to manage the impact this will have on its business, and has kept its shares on his firm's 'Americas Buy List' and 'Americas Conviction Buy List.'
JNJ 1-yr chart: